

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,735	01/28/2004		Mark G. Currie	14184-039001	4325
26161	7590	10/04/2006		EXAMINER	
FISH & RI		SON PC	TELLER, ROY R		
MINNEAPOLIS, MN 55440-1022				ART UNIT	PAPER NUMBER
•				1654	
			·	DATE MAILED: 10/04/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

1	Application No.	Applicant(s)				
	10/766,735	CURRIE ET AL.				
Office Action Summary	Examiner	Art Unit	_			
	Roy Teller	1654				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONED	I. lely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 28 Ja	nuary 2004.					
2a) ☐ This action is FINAL . 2b) ☑ This action is non-final.						
	s application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 72-89 is/are pending in the application 4a) Of the above claim(s) 75-77,79-83 and 85-8 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 72-74,78 and 84 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	39 is/are withdrawn from consider	ation.				
Application Papers						
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the confidence of Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examiner 11) The oath or declaration is objected to by the Examiner 12. **The oath of the confidence of the confid	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s)						
1) ☑ Notice of References Cited (PTO-892) 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) ☑ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 12/04,11/05.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	ite				
HOTODI ONG Landomody Office						

DETAILED ACTION

Page 2

Applicant's election with traverse of elected group I, claims 72-74, 78 and 84, drawn to the purified polypeptide of SEQ ID NO: 125, in the reply filed on 7/27/06 is acknowledged. The traversal is on the ground(s) that group II, claims 75-77, drawn to the purified polypeptide of SEQ ID NO: 126, would not impose any meaningful additional search burden on the examiner. This is not found persuasive because SEQ ID NO's 125 and 126 are drawn to different chemical structures requiring different searches as indicated by their different classifications.

The requirement is still deemed proper and is therefore made FINAL.

Claims 75-77, 79-83, and 85-89 are withdrawn as being drawn to unelected subject matter.

Claims 72-74, 78 and 84 are pending.

Information Disclosure Statement

The information disclosure statements, received 12/3/04 and 11/3/05, are acknowledged. A signed copy of each is enclosed hereto.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1654

Claims 72-74, 78 and 84 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 72-74 recited ... "wherein Xaa is selected from Phe, Trp and Tyr...". This is vague and indefinite as to the metes and bounds of SEQ ID NO: 125. The sequence listing in the instant application recites SEQ ID NO: 125 as- Xaa selected from Phe, Trp or Tyr. The examiner is unclear as to length of SEQ ID NO: 125, 13 or 16 amino acids. Clarification is requested.

All other claims depend directly or indirectly from the rejected claims and are, therefore, also rejected under 35 USC 112, second paragraph.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 72, 78, and 84 are rejected under 35 U.S.C. 102(b) as being anticipated by Giannella (J. of Lab. and Clin. Med., 1995, vol. 125, no. 2, pp-173-181).

The instant invention is drawn to a purified polypeptide comprising the amino acid sequence of SEQ ID NO: 125.

Giannella discloses E. coli heat stable enterotoxins, guanylins and their receptors. The structure of E. coli STh, a purified 19 amino acid petide is shown in figure 1, page 174. This is a 92% sequence match from C(6) to C(18) of figure 1 with SEQ ID NO: 125 of the instant

Page 4

Art Unit: 1654

invention. Applicant's claims are clearly open to other active ingredients such as peptides because of the term "comprising". "Comprising" leaves the claim open for the inclusion of unspecified ingredients even in major amounts. See MPEP 2111.03

Therefore, the reference is deemed to anticipate the instant claims above.

Conclusion

All claims are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Roy Teller whose telephone number is 571-272-0971. The examiner can normally be reached on Monday-Friday from 5:30 am to 2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang, can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1654

RT 1654 9/27/06

RT

Cecilia J. Tsang
Supervisory Patent Examiner
Technology Center 1600